Navigation Links
Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting
Date:11/21/2008

y samples were tested with the Gen-Probe APTIMA HPV assay and with Digene/Qiagen's Hybrid Capture(R) 2 assay, and the results were compared to the gold standard of histology (microscopic analysis of cervical tissue).

Dr. Monsonego concluded that in the study to date, the APTIMA HPV assay had statistically identical sensitivity, but higher specificity, than the Hybrid Capture 2 test. Other studies of the APTIMA HPV assay presented at EUROGIN showed similar results in geographically and clinically diverse patient groups. Additional details on these studies can be found in the "Science" section of the Gen-Probe website at http://www.gen-probe.com/global/science.

About the APTIMA HPV Assay

The APTIMA HPV assay is an amplified nucleic acid test that detects 14 high-risk HPV types that are associated with cervical cancer. More specifically, the assay detects two messenger RNAs (mRNAs), E6 and E7, that are made in higher amounts when HPV infections progress toward cervical cancer. Gen-Probe believes targeting these mRNAs may more accurately identify women at higher risk of having, or developing, cervical cancer than competing assays that target HPV DNA. Detecting HPV DNA identifies women who are infected, but HPV infections are common and most resolve without causing cervical cancer.

About HPV and Cervical Cancer

HPV is a group of viruses with more than 100 types, 14 of which have been categorized as high risk for the development of cervical cancer. While most women will be infected with HPV at some point in their lives, the majority of these infections are transient and resolve without any clinical symptoms or consequences. However, a small number of HPV infections progress and result in disease ranging from genital warts to cervical cancer. Since most HPV infections do not result in cancer, there is a need for a
'/>"/>

SOURCE Gen-Probe
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
2. Promising Data ATIR Studies Presented by NIH Investigators
3. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
4. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
7. AMDL ELISA DR-70(R) (FDP) is Promising as Effective Cancer Detection Test
8. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
9. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015  ValGenesis Inc., the market leader ... that it has completed its Service Organization Controls 2 ... (AICPA, Professional Standards) for the period of January 1 ... ... The SOC 2 examination is ...
(Date:4/1/2015)... , Mar. 30, 2015 Research and Markets ... addition of the "Blood Screening Market by ... Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product ... - Forecasts to 2019 " report to ... is expected to reach $2.55 billion by 2019 ...
(Date:4/1/2015)... NEW YORK , April 1, 2015 ... biopharmaceutical company advancing protein biologic therapies and oncology ... the Company,s 2014 achievements and a strategic update ... progress the Company has made in the areas ... its MuGard programs, the FDA clearance of the ...
(Date:4/1/2015)... The concept of “spot reducing” areas is a huge ... Fasciology, Ashley Black, says that even the idea of being ... to wait for the whole fat system to reduce is ... cooling procedures, the only well known way to spot ... a highly invasive procedure.” It is common knowledge that weight ...
Breaking Biology Technology:ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3
... The medical imaging company SyntheticMR AB, ... order for their magnetic resonance imaging software from Umeå ... be used in clinical practice to monitor the treatment ... SyMRI Diagnostics, includes tools to automatically estimate a measure ...
... Verenium Corporation (Nasdaq: VRNM ), a leading ... of high-performance enzymes, today announced James Levine, President and ... Mr. Levine will present at the upcoming ... September 12, 2011.  The presentation is expected to begin ...
... Switzerland, September 1, 2011 Study Assessing ... in mid 2012 Kuros Biosurgery AG, a ... and bioactive-biomaterial combination products for trauma, wound and spinal ... a Phase IIb clinical trial designed to investigate KUR-211 ...
Cached Biology Technology:Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 3Verenium to Present at Upcoming Conferences 2Verenium to Present at Upcoming Conferences 3Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers 2Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers 3
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... In 2005, the overall cost of patients' time spent on cancer ... to a new study in the January 3 issue of the ... for the 11 cancers studied and for different phases of cancer ... the direct medical costs of cancer care, but few have attempted ...
... the January issue of the journal Cell Metabolism, published by ... the formation of a poorly understood type of muscle. Moreover, ... IIX fibers were able to run farther and at higher ... ultimately lead to novel drugs designed to change the composition ...
... insect cells ?not in eggs, where flu vaccines currently available ... effective as conventional vaccines in protecting people against the flu, ... the Journal of the American Medical Association. , Removing eggs ... health officials seeking to protect the population from seasonal flu ...
Cached Biology News:Study calculates patient time costs associated with cancer care 2Study calculates patient time costs associated with cancer care 3'Marathon mice' elucidate little-known muscle type 2'Marathon mice' elucidate little-known muscle type 3Bypassing eggs, flu vaccine grown in insect cells shows promise 2Bypassing eggs, flu vaccine grown in insect cells shows promise 3
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
Biology Products: